New growth drug takes on vosoritide in kids with dwarfism

NCT ID NCT07441876

Recruiting now Disease control Sponsor: BioMarin Pharmaceutical Source: ClinicalTrials.gov ↗

First seen Apr 07, 2026 · Last updated May 24, 2026 · Updated 11 times

Summary

This study compares a new medicine, BMN 333, to an existing one (vosoritide) in 160 children with achondroplasia, the most common form of dwarfism. The goal is to see which drug works better at increasing height over one year. Children aged 2 to 17 who have not had prior growth treatment may join.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACHONDROPLASIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Consano Clinical Research, LLC
RECRUITING

California City, California, 78231, United States

Contact
Murdoch Children's Research Institute
RECRUITING

Parkville, Victoria, 3052, Australia

Contact
Texas Children Hospital, Baylor College of Medicine, Houston TX
RECRUITING

Houston, Texas, 77030, United States

Contact
UCSF Benioff Children's Hospital Oakland
RECRUITING

Oakland, California, 94609, United States

Contact

Conditions

Explore the condition pages connected to this study.

ACHONDROPLASIA